These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28238870)

  • 1. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
    Pogue JM; Ortwine JK; Kaye KS
    Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
    Pogue JM; Ortwine JK; Kaye KS
    Int J Antimicrob Agents; 2016 Dec; 48(6):622-626. PubMed ID: 27876274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
    Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
    Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aminoglycosides and polymyxins].
    Molina J; Cordero E; Palomino J; Pachón J
    Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):178-88. PubMed ID: 19303668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions associated with systemic polymyxin therapy.
    Justo JA; Bosso JA
    Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of polymyxin antibiotics.
    Kelesidis T; Falagas ME
    Expert Opin Drug Saf; 2015; 14(11):1687-701. PubMed ID: 26365594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of polymyxins to treat carbapenem resistant infections in neonates and children.
    Thomas R; Velaphi S; Ellis S; Walker AS; Standing JF; Heath P; Sharland M; Dona' D
    Expert Opin Pharmacother; 2019 Mar; 20(4):415-422. PubMed ID: 30576264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the safe use of colistin.
    Ortwine JK; Sutton JD; Kaye KS; Pogue JM
    Expert Rev Anti Infect Ther; 2015; 13(10):1237-47. PubMed ID: 26182825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polymyxins - review with emphasis on nephrotoxicity].
    Mendes CA; Burdmann EA
    Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
    Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
    Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.